Enveda Raises $311M for AI Discovery of Nature-Derived Medicines

Enveda, a biotech startup using artificial intelligence to discover medicines in plants and microbes, has raised a $311 million Series E at a $2 billion valuation. Catalio Capital Management led the financing, with Iconiq and other investors participating. The valuation is double the level Enveda achieved 12 months earlier.

The company, founded in 2019 by Viswa Colluru, is applying AI and other techniques to accelerate the search for drug candidates in the natural world. Its premise is that potent medicines can be found in biological sources rather than solely being synthesised from scratch in a laboratory.

Funding supports a clinical-stage pipeline

Enveda is not presenting its platform only as an early discovery effort. It is already testing several drugs in patients, placing the company among a group of businesses taking AI-discovered candidates into human clinical trials.

Its disclosed programmes include one aimed at severe skin conditions and another intended to help people maintain weight loss after they stop taking GLP-1 medicines. The new capital is intended to bring more nature-derived, AI-discovered drugs into clinical trials.

AI discovery still faces the approval test

The financing highlights continued investor interest in AI-enabled drug discovery, but it also sits against an important constraint: no drug produced by AI has yet received FDA approval. Moving from a computational or biological lead to a medicine requires evidence from testing in people.

Enveda’s approach focuses on plants and microbes, a distinct source of chemical diversity for prospective therapies. AI is being used to speed the identification of candidates from that natural material, while clinical work determines whether those candidates can become viable treatments.

What businesses should watch

For healthcare investors, technology leaders and drug-development partners, Enveda’s round is a reminder to distinguish discovery capability from clinical validation. A platform can accelerate the search for candidates, but patient trials remain the practical measure of whether a programme can advance toward an approved medicine.